As filed with the Securities and Exchange Commission on January 30, 2026
Registration No. 333- _______
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
BNB Plus Corp.
(Exact name of registrant as specified in its charter)
|
Delaware (State or other jurisdiction of
|
59-2262718 (I.R.S. Employer Identification Number) |
| 50 Health Sciences Drive | 11790 |
| Stony Brook, New York | (Zip Code) |
| (Address of Principal Executive Offices) |
Applied DNA Sciences, Inc. 2020 Equity Incentive Plan
(Full title of the plan)
Clay Shorrock
Chief Executive Officer and President
BNB Plus Corp.
50 Health Sciences Drive
Stony Brook, New York 11790
Telephone: (631) 240-8800
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
Copies to:
Alexander R. McClean, Esq.
Margaret K. Rhoda, Esq.
Harter Secrest & Emery LLP
1600 Bausch & Lomb Place
Rochester, New York 14604
Tel: (585) 232-6500
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ | |
| Non-accelerated filer | x | Smaller reporting company | x | |
| Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement relates to the registration of an additional 5,000,000 shares of common stock, $0.001 par value per share (the “Common Stock”), for future issuance pursuant to awards under the 2020 Equity Incentive Plan (the “2020 Plan”) of BNB Plus Corp. (the “Company”). Such additional shares being registered are of the same class as other securities of the Company for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective. In accordance with General Instruction E to Form S-8, the contents of the Company’s previous Registration Statements on Form S-8 related to the 2020 Plan (Commission File Nos. 333-249365, 333-282414, and 333-288938), filed on October 7, 2020, September 30, 2024, and July 25, 2025, respectively, with the U.S. Securities and Exchange Commission (the “Commission”), are incorporated herein by reference and made part of this Registration Statement, except as amended or otherwise modified or superseded hereby. Effective as of December 12, 2025, the date of the approval by the Company’s stockholders of the amendment of the 2020 Plan, the total number of shares of Common Stock that may be issued under the 2020 Plan has been increased to 5,200,500 shares of Common Stock from 200,500 shares of Common Stock.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The Commission allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the Commission will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents and information previously filed with the Commission:
| (i) | Our Annual Report on Form 10-K for the fiscal year ended September 30, 2025 filed with the Commission on December 22, 2025; |
| (ii) | Our Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed with the Commission on on October 1, 2025, October 6, 2025 October 23, 2025, November 4, 2025, November 10, 2025, November 17, 2025, December 15, 2025, and January 22, 2026; and |
| (iii) | The description of our Common Stock contained in our registration statement on Form 8-A (File No. 001-36745) filed on November 13, 2014, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description. |
In addition to the foregoing, all documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than, in each case, documents or information, including, without limitation, any applicable exhibits, deemed to have been “furnished” and not “filed” in accordance with the rules and regulations issued by the Commission), subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.
Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
| Item 8. | Exhibits. |
* Filed herewith.
^ Management contract or compensatory plan or arrangement.
+ This exhibit is being filed pursuant to Item 601(b)(3)(i) of Regulation S-K which requires a conformed version of the Company’s charter reflecting all amendments in one document. The exhibit reflects the Company’s Certificate of Incorporation, as previously amended, as most recently amended by the ninth Certificate of Amendment, effective November 13, 2025.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Stony Brook, State of New York, on January 30, 2026.
| BNB Plus Corp. | ||
| By: | /s/ Clay Shorrock | |
| Clay Shorrock | ||
| Chief Executive Officer and President | ||
Each person whose signature appears below appoints Clay Shorrock and Beth M. Jantzen and each of them, any of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and any registration statement (including any amendment thereto) for this offering that is to be effective upon filing pursuant to Rule 462 under the Securities Act and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or would do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them of their or his or her substitute and substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||
| /s/ Clay Shorrock | Chief Executive Officer and President | January 30, 2026 | ||
| Clay Shorrock | (Principal Executive Officer) | |||
| /s/ Beth M. Jantzen | Chief Financial Officer | January 30, 2026 | ||
| Beth M. Jantzen | (Principal Financial Officer and Principal Accounting Officer) | |||
| /s/ Joshua Kruger | Chairman of the Board of Directors | January 30, 2026 | ||
| Joshua Kruger | ||||
| /s/ Robert B. Catell | Director | January 30, 2026 | ||
| Robert B. Catell | ||||
| /s/ Joseph D. Ceccoli | Director | January 30, 2026 | ||
| Joseph D. Ceccoli | ||||
| /s/ Judith Murrah | Director | January 30, 2026 | ||
| Judith Murrah | ||||
| /s/ Yacov A. Shamash | Director | January 30, 2026 | ||
| Yacov A. Shamash |
Exhibit 5.1

January 30, 2026
BNB Plus Corp.
50 Health Sciences Drive
Stony Brook, New York 11790
Re: Registration Statement on Form S-8
Ladies and Gentlemen:
We have acted as counsel to BNB Plus Corp. (formerly known as Applied DNA Sciences, Inc.), a Delaware corporation (the “Company”), in connection with its filing of a Registration Statement on Form S-8, together with the exhibits thereto (the “Registration Statement”) to be filed on the date hereof, with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”) with respect to the registration of an additional 5,000,000 shares of the Company’s common stock (the “Shares”), par value $0.001 per share (the “Common Stock”), reserved for issuance pursuant to the terms of the Company’s 2020 Equity Incentive Plan, as amended (the “Plan”). This opinion is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K, 17 C.F.R. § 229.601(b)(5), in connection with the filing of the Registration Statement.
For purposes of this opinion, we have with your permission made the following assumptions, in each case without independent verification: (i) the due authorization, execution and delivery of all documents by all the parties thereto; (ii) the genuineness of all signatures on all documents submitted to us; (iii) the authenticity and completeness of all documents, corporate records, certificates and other instruments (the “Records”) submitted to us; (iv) that photocopy, electronic, certified, conformed, facsimile and other copies submitted to us of the Records conform to the original Records; (v) the legal capacity of all individuals executing documents; (vi) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for the purposes of this opinion are true and correct; and (vii) that at the time the Shares are issued, the Company will be validly existing and there will be sufficient Shares authorized under the Company’s certificate of incorporation, as amended and then in effect, and not otherwise issued or reserved for issuance. As to all questions of fact material to this opinion, we have relied (without independent verification) upon certificates or comparable documents of officers and representatives of the Company.
Based upon, subject to and limited by the foregoing, we are of the opinion that following (i) effectiveness of the Registration Statement with the SEC, (ii) issuance of the Shares in accordance with the terms and conditions of the Plan, and (iii) receipt by the Company of the legal consideration for the Shares as specified in the Plan in an amount no less than the par value of such Shares, the Shares will be validly issued, fully paid and non-assessable.
| 1600 BAUSCH & LOMB PLACE ROCHESTER, NY 14604-2711 PHONE: 585.232.6500 FAX: 585.232.2152 |
| rochester, ny • buffalo, ny • albany, ny • corning, ny • new york, ny |

BNB Plus Corp.
January 30, 2026
Page 2
We express no opinion with respect to the effect of any law other than the applicable provisions of the Delaware General Corporate Law as currently in effect.
This opinion letter has been prepared in accordance with the customary practice of lawyers who regularly give, and lawyers who regularly advise opinion recipients concerning, opinions of the type contained herein.
This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly addressed herein from any matter stated in this letter.
We consent to the use of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act and the rules and regulations thereunder. This opinion is rendered to you as of the date hereof and we assume no obligation to advise you or any other person hereafter with regard to any change after the date hereof in the circumstances or the law that may bear on the matters set forth herein even though the changes may affect the legal analysis or legal conclusion or other matters in this letter.
| Very truly yours, | |
|
/s/ Harter Secrest & Emery LLP
| |
Exhibit 10.1
APPLIED DNA SCIENCES, INC.
2020 EQUITY INCENTIVE PLAN
Section 1. Purpose; Definitions. The purposes of the Applied DNA Sciences, Inc. 2020 Equity Incentive Plan (as amended from time to time, the “Plan”) are to: (a) enable Applied DNA Sciences, Inc. (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide those employees, directors and consultants with an incentive for productivity; and (c) provide those employees, directors and consultants with an opportunity to share in the growth and value of the Company.
For purposes of the Plan, the following terms will have the meanings defined below, unless the context clearly requires a different meaning:
(a) “Affiliate” means, with respect to a Person, a Person that directly or indirectly controls, is controlled by, or is under common control with such Person.
(b) “Applicable Law” means the legal requirements relating to the administration of and issuance of securities under stock incentive plans, including, without limitation, the requirements of state corporations law, federal, state and foreign securities law, federal, state and foreign tax law, and the requirements of any stock exchange or quotation system upon which the Shares may then be listed or quoted.
(c) “Award” means an award of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Cash or Other Stock Based Awards made under this Plan.
(d) “Award Agreement” means, with respect to any particular Award, the written document that sets forth the terms of that particular Award.
(e) “Board” means the Board of Directors of the Company, as constituted from time to time.
(f) “Cash or Other Stock Based Award” means an award that is granted under Section 10.
(g) “Cause” means (i) Participant’s refusal to comply with any lawful directive or policy of the Company which refusal is not cured by the Participant within ten (10) days of such written notice from the Company; (ii) the Company’s determination that Participant has committed any act of dishonesty, embezzlement, unauthorized use or disclosure of confidential information or other intellectual property or trade secrets, common law fraud or other fraud against the Company or any Subsidiary or Affiliate; (iii) a material breach by the Participant of any written agreement with or any fiduciary duty owed to any Company or any Subsidiary or Affiliate; (iv) Participant’s conviction (or the entry of a plea of a nolo contendere or equivalent plea) of a felony or any misdemeanor involving material dishonesty or moral turpitude; or (v) Participant’s habitual or repeated misuse of, or habitual or repeated performance of Participant’s duties under the influence of, alcohol, illegally obtained prescription controlled substances or non-prescription controlled substances. Notwithstanding the foregoing, if a Participant and the Company (or any of its Affiliates) have entered into an employment agreement, consulting agreement or other similar agreement that specifically defines “cause,” then with respect to such Participant, “Cause” shall have the meaning defined in such other agreement.
| 1 |
(h) “Change in Control” shall mean the occurrence of any of the following events: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total power to vote for the election of directors of the Company; (ii) during any twelve month period, individuals who at the beginning of such period constitute the Board and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Section 1(h) (i), Section 1(h)(iii), Section 1(h)(iv) or Section 1(h)(v) hereof) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period of whose election or nomination for election was previously approved, cease for any reason to constitute a majority thereof; (iii) the merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to 50% or more of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); (iv) the sale or other disposition of all or substantially all of the assets of the Company; (v) a liquidation or dissolution of the Company; or (vi) such other event deemed to constitute a “Change in Control” by the Board.
Notwithstanding anything in the Plan or an Award Agreement to the contrary, to the extent necessary to comply with Section 409A of the Code, no event that, but for the application of this paragraph, would be a Change in Control as defined in the Plan or the Award Agreement, as applicable, shall be a Change in Control unless such event is also a “change in control event” as defined in Section 409A of the Code.
(i) “Code” means the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto.
(j) “Committee” means the committee designated by the Board to administer the Plan under Section 2. To the extent required under Applicable Law, the Committee shall have at least two members and each member of the Committee shall be a Non-Employee Director.
(k) “Director” means a member of the Board.
(l) “Disability” means a condition rendering a Participant Disabled.
| 2 |
(m) “Disabled” will have the same meaning as set forth in Section 22(e)(3) of the Code.
(n) “Exchange Act” means the Securities Exchange Act of 1934, as amended.
(o) “Fair Market Value” means, as of any date, the value of a Share determined as follows: (i) if the Shares are listed on any established stock exchange or a national market system, including, without limitation, the Nasdaq Capital Market, the Fair Market Value of a Share will be the closing sales price for such stock as quoted on that system or exchange (or the system or exchange with the greatest volume of trading in Shares) at the close of regular hours trading on the day of determination; (ii) if the Shares are regularly quoted by recognized securities dealers but selling prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for Shares at the close of regular hours trading on the day of determination; or (iii) if Shares are not traded as set forth above, the Fair Market Value will be determined in good faith by the Committee taking into consideration such factors as the Committee considers appropriate, such determination by the Committee to be final, conclusive and binding. Notwithstanding the foregoing, in connection with a Change in Control, Fair Market Value shall be determined in good faith by the Committee, such determination by the Committee to be final conclusive and binding.
(p) “Incentive Stock Option” means any Option intended to be an “Incentive Stock Option” within the meaning of Section 422 of the Code.
(q) “Non-Employee Director” will have the meaning set forth in Rule 16b-3(b)(3)(i) promulgated by the Securities and Exchange Commission under the Exchange Act, or any successor definition adopted by the Securities and Exchange Commission.
(r) “Non-Qualified Stock Option” means any Option that is not an Incentive Stock Option.
(s) “Option” means any option to purchase Shares (including an option to purchase Restricted Stock, if the Committee so determines) granted pursuant to Section 5 hereof.
(t) “Parent” means, in respect of the Company, a “parent corporation” as defined in Section 424(e) of the Code.
(u) “Participant” means an employee, consultant, Director, or other service provider of or to the Company or any of its respective Affiliates to whom an Award is granted.
(v) “Person” means an individual, partnership, corporation, limited liability company, trust, joint venture, unincorporated association, or other entity or association.
(w) “Restricted Stock” means Shares that are subject to restrictions pursuant to Section 8 hereof.
| 3 |
(x) “Restricted Stock Unit” means a right granted under and subject to restrictions pursuant to Section 9 hereof.
(y) “Shares” means shares of the Company’s common stock, par value $0.001, subject to substitution or adjustment as provided in Section 3(d) hereof.
(z) “Stock Appreciation Right” means a right granted under and subject to Section 6 hereof.
(aa) “Subsidiary” means, in respect of the Company, a subsidiary company as defined in Sections 424(f) and (g) of the Code.
Section 2. Administration. The Plan shall be administered by the Committee; provided that, notwithstanding anything to the contrary herein, in its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Committee under the Plan except with respect to matters which under Applicable Law are required to be determined in the sole discretion of the Committee. Any action of the Committee in administering the Plan shall be final, conclusive and binding on all persons, including the Company, its Subsidiaries, Affiliates, their respective employees, the Participants, persons claiming rights from or through Participants and stockholders of the Company. The Committee will have full authority to grant Awards under this Plan and determine the terms of such Awards. Such authority will include the right to:
(a) select the individuals to whom Awards are granted (consistent with the eligibility conditions set forth in Section 4);
(b) determine the type of Award to be granted;
(c) determine the number of Shares, if any, to be covered by each Award;
(d) establish the other terms and conditions of each Award;
(e) approve forms of agreements (including Award Agreements) for use under the Plan; and
(f) modify or amend each Award, subject to the Participant’s consent if such modification or amendment would materially impair such Participant’s rights.
The Committee will have the authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan as it, from time to time, deems advisable; to interpret the terms and provisions of the Plan and any Award issued under the Plan (and any Award Agreement); and to otherwise take any action that may be necessary or desirable to facilitate the administration of the Plan. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award Agreement in the manner and to the extent it deems necessary to carry out the intent of the Plan.
| 4 |
To the extent permitted by Applicable Law, the Committee may delegate to one or more officers of the Company the authority to grant Awards to Participants who are not subject to the requirements of Section 16 of the Exchange Act and the rules and regulations thereunder. Any such delegation shall be subject to the applicable corporate laws of the State of Delaware. The Committee may revoke any such allocation or delegation at any time for any reason with or without prior notice.
No Director will be liable for any good faith determination, act or omission in connection with the Plan or any Award.
Section 3. Shares Subject to the Plan.
(a) Shares Subject to the Plan. Subject to adjustment as provided in Section 3(d) of the Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is 7,500 (the “Plan Limit”). Subject to adjustment as provided in Section 3(d) of the Plan, the maximum aggregate number of Shares that may be issued under the Plan in respect of Incentive Stock Options is 7,500. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan. The maximum total grant date fair value of Awards (as measured by the Company for financial accounting purposes) granted to any Participant in his or her capacity as a Non-Employee Director in any single calendar year shall not exceed $250,000.
(b) Effect of the Expiration or Termination of Awards. If and to the extent that an Option or a Stock Appreciation Right expires, terminates or is canceled or forfeited for any reason without having been exercised in full, the Shares associated with that Award will again become available for grant under the Plan. Similarly, if and to the extent an Award of Restricted Stock or Restricted Stock Units is canceled or forfeited for any reason, the Shares subject to that Award will again become available for grant under the Plan. In addition, if any award granted under the Applied DNA Sciences, Inc. 2005 Incentive Stock Plan (as amended) expires, terminates, is canceled or is forfeited for any reason after the Effective Date, the Shares subject to that award will be added to the Plan Limit and become available for issuance hereunder.
(c) Shares Withheld in Satisfaction of Taxes or Exercise Price. Shares withheld in settlement of a tax withholding obligation associated with an Award, or in satisfaction of the exercise price payable upon exercise of an Option, will not again become available for grant under the Plan.
(d) Other Adjustment. In the event of any corporate event or transaction such as a merger, consolidation, reorganization, recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock dividend, dividend in kind, or other like change in capital structure (other than ordinary cash dividends) to stockholders of the Company, or other similar corporate event or transaction affecting the Shares, the Committee, to prevent dilution or enlargement of Participants’ rights under the Plan, shall, in such manner as it may deem equitable, substitute or adjust, in its sole discretion, the number and kind of shares that may be issued under the Plan or under any outstanding Awards, the number and kind of shares subject to outstanding Awards, the exercise price, grant price or purchase price applicable to outstanding Awards, and/or any other affected terms and conditions of this Plan or outstanding Awards.
| 5 |
(e) Change in Control. Notwithstanding anything to the contrary set forth in the Plan, upon or in anticipation of any Change in Control, the Committee may, in its sole and absolute discretion and without the need for the consent of any Participant, take one or more of the following actions contingent upon the occurrence of that Change in Control:
(i) cause any or all outstanding Awards to become vested and immediately exercisable (as applicable), in whole or in part;
(ii) cause any outstanding Option or Stock Appreciation Right to become fully vested and immediately exercisable for a reasonable period in advance of the Change in Control and, to the extent not exercised prior to that Change in Control, cancel that Option or Stock Appreciation Right upon closing of the Change in Control;
(iii) cancel any unvested Award or unvested portion thereof, with or without consideration;
(iv) cancel any Award in exchange for a substitute award;
(v) redeem any Restricted Stock or Restricted Stock Unit for cash and/or other substitute consideration with value equal to the Fair Market Value of an unrestricted Share on the date of the Change in Control;
(vi) cancel any Option or Stock Appreciation Right in exchange for cash and/or other substitute consideration with a value equal to: (A) the number of Shares subject to that Option or Stock Appreciation Right, multiplied by (B) the difference, if any, between the Fair Market Value per Share on the date of the Change in Control and the exercise price of that Option or the base price of the Stock Appreciation Right; provided, that if the Fair Market Value per Share on the date of the Change in Control does not exceed the exercise price of any such Option or the base price of any such Stock Appreciation Right, the Committee may cancel that Option or Stock Appreciation Right without any payment of consideration therefor; and/or
(vii) take such other action as the Committee shall determine to be reasonable under the circumstances.
In the discretion of the Committee, any cash or substitute consideration payable upon cancellation of an Award may be subjected to (i) vesting terms substantially identical to those that applied to the cancelled Award immediately prior to the Change in Control, or (ii) earn-out, escrow, holdback or similar arrangements, to the extent such arrangements are applicable to any consideration paid to stockholders in connection with the Change in Control.
| 6 |
Notwithstanding any provision of this Section 3(e), in the case of any Award subject to Section 409A of the Code, the Committee shall only be permitted to take actions under this Section 3(e) to the extent that such actions would be consistent with the intended treatment of such Award under Section 409A of the Code.
(f) Foreign Holders. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in countries other than the United States in which the Company and its Subsidiaries operate or have employees, directors and consultants, or in order to comply with the requirements of any foreign securities exchange or other Applicable Law, the Committee, in its sole discretion, shall have the power and authority to: (i) modify the terms and conditions of any Award granted to employees, directors and consultants outside the United States to comply with Applicable Law (including, without limitation, applicable foreign laws or listing requirements of any foreign securities exchange); (ii) establish subplans and modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or advisable; provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a); and (iii) take any action, before or after an Award is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals or listing requirements of any foreign securities exchange.
Section 4. Eligibility. Employees, Directors, consultants, and other individuals who provide services to the Company or its Affiliates are eligible to be granted Awards under the Plan; provided, however, that only employees of the Company, any Parent or a Subsidiary are eligible to be granted Incentive Stock Options.
Section 5. Options. Options granted under the Plan may be of two types: (i) Incentive Stock Options or (ii) Non-Qualified Stock Options. The Award Agreement shall state whether such grant is an Incentive Stock Option or a Non-Qualified Stock Option.
The Award Agreement evidencing any Option will incorporate the following terms and conditions and will contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion:
(a) Option Price. The exercise price per Share under an Option will be determined by the Committee and will not be less than 100% of the Fair Market Value of a Share on the date of the grant. However, any Incentive Stock Option granted to any Participant who, at the time the Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section 424(d) of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, will have an exercise price per Share of not less than 110% of Fair Market Value per Share on the date of the grant.
(b) Option Term. The term of each Option will be fixed by the Committee, but no Option will be exercisable more than 10 years after the date the Option is granted. However, any Incentive Stock Option granted to any Participant who, at the time such Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section 424(d) of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, may not have a term of more than 5 years. No Option may be exercised by any Person after expiration of the term of the Option.
| 7 |
(c) Exercisability. Options will vest and be exercisable at such time or times and subject to such terms and conditions as determined by the Committee. Such terms and conditions may include the continued employment or service of the Participant, the attainment of specified individual or corporate performance goals, or such other factors as the Committee may determine in its sole discretion (the “Vesting Conditions”). The Committee may provide in the terms of an Award Agreement that the Participant may exercise the unvested portion of an Option in whole or in part in exchange for shares of Restricted Stock subject to the same vesting terms as the portion of the Option so exercised. Restricted Stock acquired upon the exercise of an unvested Option shall be subject to such additional terms and conditions as determined by the Committee.
(d) Method of Exercise. Subject to the terms of the applicable Award Agreement, the exercisability provisions of Section 5(c) and the termination provisions of Section 7, Options may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying the number of Shares to be purchased. Such notice will be accompanied by payment in full of the purchase price, either by certified or bank check, or such other means as the Committee may accept. The Committee may, in its sole discretion, permit payment of the exercise price of an Option in the form of previously acquired Shares based on the Fair Market Value of the Shares on the date the Option is exercised or by means of a “net settlement,” whereby the Option exercise price will not be due in cash and where the number of Shares issued upon such exercise will be equal to: (A) the product of (i) the number of Shares as to which the Option is then being exercised, and (ii) the excess, if any, of (a) the then current Fair Market Value per Share over (b) the Option exercise price, divided by (B) the then current Fair Market Value per Share.
No Shares will be issued upon exercise of an Option until full payment therefor has been made. A Participant will not have the right to distributions or dividends or any other rights of a stockholder with respect to Shares subject to the Option until the Participant has given written notice of exercise, has paid in full for such Shares, if requested, has given the representation described in Section 17(a) hereof and fulfills such other conditions as may be set forth in the applicable Award Agreement.
(e) Incentive Stock Option Limitations. In the case of an Incentive Stock Option, the aggregate Fair Market Value (determined as of the time of grant) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year under the Plan and/or any other plan of the Company, its Parent or any Subsidiary will not exceed $100,000. For purposes of applying the foregoing limitation, Incentive Stock Options will be taken into account in the order granted. To the extent any Option does not meet such limitation, that Option will be treated for all purposes as a Non-Qualified Stock Option.
(f) Termination of Service. Unless otherwise specified in the applicable Award Agreement or as otherwise provided by the Committee at or after the time of grant, Options will be subject to the terms of Section 7 with respect to exercise upon or following termination of employment or other service.
| 8 |
Section 6. Stock Appreciation Right. Subject to the other terms of the Plan, the Committee may grant Stock Appreciation Rights to eligible individuals. Each Stock Appreciation Right shall represent the right to receive, upon exercise, an amount equal to the number of Shares subject to the Award that is being exercised multiplied by the excess of (i) the Fair Market Value of a Share on the date the Award is exercised, over (ii) the base price specified in the applicable Award Agreement. Distributions may be made in cash, Shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing each Stock Appreciation Right shall indicate the base price, the term and the Vesting Conditions for such Award. A Stock Appreciation Right base price may never be less than the Fair Market Value of the underlying common stock of the Company on the date of grant of such Stock Appreciation Right. The term of each Stock Appreciation Right will be fixed by the Committee, but no Stock Appreciation Right will be exercisable more than 10 years after the date the Stock Appreciation Right is granted. Subject to the terms and conditions of the applicable Award Agreement, Stock Appreciation Rights may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying the portion of the Award to be exercised. Unless otherwise specified in the applicable Award Agreement or as otherwise provided by the Committee at or after the time of grant, Stock Appreciation Rights will be subject to the terms of Section 7 with respect to exercise upon or following termination of employment or other service.
Section 7. Termination of Service. Unless otherwise specified with respect to a particular Option or Stock Appreciation Right in the applicable Award Agreement or otherwise determined by the Committee, any portion of an Option or Stock Appreciation Right that is not exercisable upon termination of service will expire immediately and automatically upon such termination and any portion of an Option or Stock Appreciation Right that is exercisable upon termination of service will expire on the date it ceases to be exercisable in accordance with this Section 7.
(a) Termination by Reason of Death. If a Participant’s service with the Company or any Affiliate terminates by reason of death, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised, to the extent it was exercisable at the time of his or her death or on such accelerated basis as the Committee may determine at or after grant, by the legal representative of the estate or by the legatee of the Participant, for a period expiring (i) at such time as may be specified by the Committee at or after grant, or (ii) if not specified by the Committee, then 12 months from the date of death, or (iii) if sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation Right.
(b) Termination by Reason of Disability. If a Participant’s service with the Company or any Affiliate terminates by reason of Disability, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised by the Participant or his or her personal representative, to the extent it was exercisable at the time of termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i) at such time as may be specified by the Committee at or after grant, or (ii) if not specified by the Committee, then 12 months from the date of termination of service, or (iii) if sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation Right.
| 9 |
(c) Cause. If a Participant’s service with the Company or any Affiliate is terminated for Cause or if a Participant resigns at a time that there was a Cause basis for such Participant’s termination: any Option or Stock Appreciation Right, or portion thereof, not already exercised will be immediately and automatically forfeited as of the date of such termination, and (ii) any Shares for which the Company has not yet delivered share certificates will be immediately and automatically forfeited and the Company will refund to the Participant the Option exercise price paid for such Shares, if any.
(d) Other Termination. If a Participant’s service with the Company or any Affiliate terminates for any reason other than death, Disability or Cause, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised by the Participant, to the extent it was exercisable at the time of such termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i) at such time as may be specified by the Committee at or after grant, or (ii) if not specified by the Committee, then 90 days from the date of termination of service, or (iii) if sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation Right.
Section 8. Restricted Stock.
(a) Issuance. Restricted Stock may be issued either alone or in conjunction with other Awards. The Committee will determine the time or times within which Restricted Stock may be subject to forfeiture, and all other conditions of such Awards. The purchase price for Restricted Stock may, but need not, be zero.
(b) Certificates. Upon the Award of Restricted Stock, the Committee may direct that a certificate or certificates representing the number of Shares subject to such Award be issued to the Participant or placed in a restricted stock account (including an electronic account) with the transfer agent and in either case designating the Participant as the registered owner. The certificate(s), if any, representing such shares shall be physically or electronically legended, as applicable, as to sale, transfer, assignment, pledge or other encumbrances during the Restriction Period. If physical certificates are issued, they will be held in escrow by the Company or its designee during the Restriction Period. As a condition to any Award of Restricted Stock, the Participant may be required to deliver to the Company a share power, endorsed in blank, relating to the Shares covered by such Award.
| 10 |
(c) Restrictions and Conditions. The Award Agreement evidencing the grant of any Restricted Stock will incorporate the following terms and conditions and such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion:
(i) During a period commencing with the date of an Award of Restricted Stock and ending at such time or times as specified by the Committee (the “Restriction Period”), the Participant will not be permitted to sell, transfer, pledge, assign or otherwise encumber Restricted Stock awarded under the Plan. The Committee may condition the lapse of restrictions on Restricted Stock upon one or more Vesting Conditions.
(ii) While any Share of Restricted Stock remains subject to restriction, the Participant will have, with respect to the Restricted Stock, the right to vote the Shares. If any cash distributions or dividends are payable with respect to the Restricted Stock, the Committee, in its sole discretion, may require the cash distributions or dividends to be subjected to the same Restriction Period as is applicable to the Restricted Stock with respect to which such amounts are paid, or, if the Committee so determines, reinvested in additional Restricted Stock to the extent Shares are available under Section 3(a) of the Plan. A Participant shall not be entitled to interest with respect to any dividends or distributions subjected to the Restriction Period. Any distributions or dividends paid in the form of securities with respect to Restricted Stock will be subject to the same terms and conditions as the Restricted Stock with respect to which they were paid, including, without limitation, the same Restriction Period.
(iii) Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant’s service with the Company and its Affiliates terminates prior to the expiration of the applicable Restriction Period, the Participant’s Restricted Stock that then remains subject to forfeiture will then be forfeited automatically.
Section 9. Restricted Stock Units. Subject to the other terms of the Plan, the Committee may grant Restricted Stock Units to eligible individuals and may impose one or more Vesting Conditions on such units. Each Restricted Stock Unit will represent a right to receive from the Company, upon fulfillment of any applicable conditions, an amount equal to the Fair Market Value (at the time of the distribution) of one Share. Distributions may be made in cash, Shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing a Restricted Stock Unit shall set forth the Vesting Conditions and time and form of payment with respect to such Award. The Participant shall not have any stockholder rights with respect to the Shares subject to a Restricted Stock Unit Award until that Award vests and the Shares are actually issued thereunder; provided, however, that an Award Agreement may provide for the inclusion of dividend equivalent payments or unit credits with respect to the Award in the discretion of the Committee. Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant’s service with the Company terminates prior to the Restricted Stock Unit Award vesting in full, any portion of the Participant’s Restricted Stock Units that then remain subject to forfeiture will then be forfeited automatically.
Section 10. Cash or Other Stock Based Awards. Subject to the other terms of the Plan, the Committee may grant Cash or Other Stock Based Awards (including Awards to receive unrestricted Shares or immediate cash payments) to eligible individuals. The Award Agreement evidencing a Cash or Other Stock Based Award shall set forth the terms and conditions of such Cash or Other Stock Based Award, including, as applicable, the term, any exercise or purchase price, performance goals, Vesting Conditions and other terms and conditions. Payment in respect of a Cash or Other Stock Based Award may be made in cash, Shares, or a combination of cash and Shares, as determined by the Committee.
| 11 |
Section 11. Amendments and Termination. Subject to any stockholder approval that may be required under Applicable Law, the Plan may be amended or terminated at any time or from time to time by the Board.
Section 12. Prohibition on Repricing Programs. Neither the Committee nor the Board shall (i) implement any cancellation/re-grant program pursuant to which outstanding Options or Stock Appreciation Rights under the Plan are cancelled and new Options or Stock Appreciation Rights are granted in replacement with a lower exercise or base price per share, (ii) cancel outstanding Options or Stock Appreciation Rights under the Plan with exercise prices or base prices per share in excess of the then current Fair Market Value per Share for consideration payable in equity securities of the Company or (iii) otherwise directly reduce the exercise price or base price in effect for outstanding Options or Stock Appreciation Rights under the Plan, without in each such instance obtaining stockholder approval.
Section 13. Conditions Upon Grant of Awards and Issuance of Shares.
(a) The implementation of the Plan, the grant of any Award and the issuance of Shares in connection with the issuance, exercise or vesting of any Award made under the Plan shall be subject to the Company’s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the Awards made under the Plan and the Shares issuable pursuant to those Awards.
(b) No Shares or other assets shall be issued or delivered under the Plan unless and until there shall have been compliance with all applicable requirements of Applicable Law.
Section 14. Limits on Transferability; Beneficiaries. No Award or other right or interest of a Participant under the Plan shall be pledged, encumbered, or hypothecated to, or in favor of, or subject to any lien, obligation, or liability of such Participant to, any party, other than the Company, any Subsidiary or Affiliate, or assigned or transferred by such Participant other than by will or the laws of descent and distribution, and such Awards and rights shall be exercisable during the lifetime of the Participant only by the Participant or his or her guardian or legal representative. Notwithstanding the foregoing, the Committee may, in its discretion, provide that Awards or other rights or interests of a Participant granted pursuant to the Plan (other than an Incentive Stock Option) be transferable, without consideration, to immediate family members (i.e., children, grandchildren or spouse), to trusts for the benefit of such immediate family members and to partnerships in which such family members are the only partners. The Committee may attach to such transferability feature such terms and conditions as it deems advisable. In addition, a Participant may, in the manner established by the Committee, designate a beneficiary (which may be a person or a trust) to exercise the rights of the Participant, and to receive any distribution, with respect to any Award upon the death of the Participant. A beneficiary, guardian, legal representative or other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award Agreement applicable to such Participant, except as otherwise determined by the Committee, and to any additional restrictions deemed necessary or appropriate by the Committee.
| 12 |
Section 15. Withholding of Taxes.
(a) Required Withholding. All Awards under the Plan shall be subject to applicable federal (including FICA), state and local tax withholding requirements. The Company may require that the Participant or other person receiving or exercising Awards pay to the Company the amount of any federal, state or local taxes that the Company is required to withhold with respect to such Awards, or the Company may deduct from other wages paid by the Company the amount of any withholding taxes due with respect to such Awards.
(b) Election to Withhold Shares. If the Committee so permits, Shares subject to an Award may be withheld to satisfy tax withholding obligations arising with respect thereto based on the Fair Market Value of such Shares at the time of withholding, to the extent that such withholding would not result in liability classification of such Award (or any portion thereof) under applicable accounting rules.
Section 16. Liability of Company.
(a) Inability to Obtain Authority. If the Company cannot, by the exercise of commercially reasonable efforts, obtain authority from any regulatory body having jurisdiction for the sale of any hares under this Plan, and such authority is deemed by the Company’s counsel to be necessary to the lawful issuance of those Shares, the Company will be relieved of any liability for failing to issue or sell those Shares.
(b) Grants Exceeding Allotted Shares. If Shares subject to an Award exceed, as of the date of grant, the number of Shares which may be issued under the Plan without additional stockholder approval, that Award will be contingent with respect to such excess Shares, on the effectiveness under Applicable Law of a sufficient increase in the number of Shares subject to this Plan.
(c) Rights of Participants and Beneficiaries. The Company will pay all amounts payable under this Plan only to the applicable Participant, or beneficiaries entitled thereto pursuant to this Plan. The Company will not be liable for the debts, contracts, or engagements of any Participant or his or her beneficiaries, and rights to cash payments under this Plan may not be taken in execution by attachment or garnishment, or by any other legal or equitable proceeding while in the hands of the Company.
Section 17. General Provisions.
(a) The Board may require each Participant to represent to and agree with the Company in writing that the Participant is acquiring securities of the Company for investment purposes and without a view to distribution thereof and as to such other matters as the Board believes are appropriate.
| 13 |
(b) The Awards shall be subject to the Company’s stock ownership policies, as in effect from time to time.
(c) All certificates for Shares or other securities delivered under the Plan will be subject to such share-transfer orders and other restrictions as the Board may deem advisable under the rules, regulations and other requirements of the Securities Act of 1933, as amended, the Exchange Act, any stock exchange upon which the Shares are then listed, and any other Applicable Law, and the Board may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.
(d) Nothing contained in the Plan will prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required.
(e) Neither the adoption of the Plan nor the execution of any document in connection with the Plan will: (i) confer upon any employee or other service provider of the Company or an Affiliate any right to continued employment or engagement with the Company or such Affiliate, or (ii) interfere in any way with the right of the Company or such Affiliate to terminate the employment or engagement of any of its employees or other service providers at any time.
(f) The Awards (whether vested or unvested) shall be subject to rescission, cancellation or recoupment, in whole or in part, under any current or future “clawback” or similar policy of the Company that is applicable to the Participant. Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement.
Section 18. Effective Date of Plan. The Plan will become effective upon its approval by the holders of a majority of the voting power of the shares deemed present and entitled to vote at the meeting of stockholders of the Company (the “Effective Date”).
Section 19. Term of Plan. Unless the Plan shall theretofore have been terminated in accordance with Section 11, the Plan shall terminate on the 10-year anniversary of the Effective Date, and no Awards under the Plan shall thereafter be granted.
Section 20. Invalid Provisions. In the event that any provision of this Plan is found to be invalid or otherwise unenforceable under any Applicable Law, such invalidity or unenforceability will not be construed as rendering any other provisions contained herein as invalid or unenforceable, and all such other provisions will be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained herein.
Section 21. Governing Law. The Plan and all Awards granted hereunder will be governed by and construed in accordance with the laws and judicial decisions of the State of Delaware, without regard to the application of the principles of conflicts of laws.
| 14 |
Section 22. Notices. Any notice to be given to the Company pursuant to the provisions of this Plan must be given in writing and addressed, if to the Company, to its principal executive office to the attention of its Chief Financial Officer (or such other Person as the Company may designate in writing from time to time), and, if to a Participant, to the address contained in the Company’s personnel files, or at such other address as that Participant may hereafter designate in writing to the Company. Any such notice will be deemed duly given: if delivered personally or via recognized overnight delivery service, on the date and at the time so delivered; if sent via telecopier or email, on the date and at the time telecopied or emailed with confirmation of delivery; or, if mailed, five (5) days after the date of mailing by registered or certified mail.
| 15 |
AMENDMENT TO THE
APPLIED DNA SCIENCES, INC.
2020 EQUITY INCENTIVE PLAN
The Applied DNA Sciences, Inc. 2020 Equity Incentive Plan (the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Applied DNA Sciences, Inc. (the “Company”):
1. Section 3(a) of the Plan is amended in its entirety; provided that Section 3(a), as amended, is subject to approval by the Company’s stockholders in accordance with Section 11 of the Plan:
(a) Shares Subject to the Plan. Subject to adjustment as provided in Section 3(d) of the Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is 5,200,500 (the “Plan Limit”). Subject to adjustment as provided in Section 3(d) of the Plan, the maximum aggregate number of Shares that may be issued under the Plan in respect of Incentive Stock Options is 5,200,500. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan. The maximum total grant date fair value of Awards (as measured by the Company for financial accounting purposes) granted to any Participant in his or her capacity as a Non-Employee Director in any single calendar year shall not exceed $250,000.
* * *
Except as amended hereby, the terms and conditions of the Plan shall otherwise continue in full force and effect.
Exhibit 23.2
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated December 17, 2024, except for Note K, as to which is December 19, 2025 relating to the financial statements appearing in the Annual Report on Form 10-K of BNB Plus Corp. (formerly Applied DNA Sciences, Inc.) for the year ended September 30, 2024.
/s/ Marcum llp
Melville, NY
January 29, 2026
Exhibit 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated December 19, 2025 with respect to the financial statements of BNB Plus Corp. (formerly Applied DNA Sciences, Inc.) for the year ended September 30, 2025 included in the Annual Report on Form 10-K.
/s/ CBIZ CPAs P.C.
Melville, NY
January 29, 2026
|
Calculation of Filing Fee Tables |
|||
|
|
|||
|
|
|||
|
Table 1: Newly Registered Securities |
|---|
|
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee |
|
|---|---|---|---|---|---|---|---|---|
| 1 |
|
|
|
|
$
|
$
|
|
$
|
|
Total Offering Amounts: |
$
|
$
|
||||||
|
Total Fee Offsets: |
$
|
|||||||
|
Net Fee Due: |
$
|
|||||||
|
Offering Note |
|
1 |
|
||||||
|
|
|||||||
| Table 2: Fee Offset Claims and Sources |
|---|
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rule 457(p) | |||||||||||||
| Fee Offset Claims | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Fee Offset Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
Submission |
Jan. 28, 2026 |
|---|---|
| Submission [Line Items] | |
| Central Index Key | 0000744452 |
| Registrant Name | BNB PLUS CORP. |
| Form Type | S-8 |
| Submission Type | S-8 |
| Fee Exhibit Type | EX-FILING FEES |
| Offering Table N/A | |
| Offset Table N/A | N/A |
Offerings - Offering: 1 |
Jan. 28, 2026
USD ($)
shares
|
|---|---|
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common Stock, par value $0.001 per share |
| Amount Registered | shares | 5,000,000 |
| Proposed Maximum Offering Price per Unit | 1.55 |
| Maximum Aggregate Offering Price | $ 7,750,000.00 |
| Fee Rate | 0.01381% |
| Amount of Registration Fee | $ 1,070.27 |
| Offering Note | Pursuant to Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of BNB Plus Corp. (the "Company") common stock, $0.001 par value per share (the "Common Stock"), which become issuable under the Applied DNA Sciences, Inc. 2020 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of the Company. Estimated in accordance with Rules 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high ($1.59) and low ($1.50) prices of the Common Stock as reported on The Nasdaq Capital Market on January 27, 2026. |
Fees Summary |
Jan. 28, 2026
USD ($)
|
|---|---|
| Fees Summary [Line Items] | |
| Total Offering | $ 7,750,000.00 |
| Total Fee Amount | 1,070.27 |
| Total Offset Amount | 0.00 |
| Net Fee | $ 1,070.27 |
{
"version": "2.2",
"instance": {
"tm264258d1_ex-filingfees.htm": {
"dts": {
"inline": {
"local": [
"tm264258d1_ex-filingfees.htm"
]
},
"schema": {
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
"https://xbrl.sec.gov/ffd/2025q4/ffd-2025q4.xsd"
]
}
},
"keyStandard": 21,
"keyCustom": 0,
"axisStandard": 1,
"axisCustom": 0,
"memberStandard": 1,
"memberCustom": 0,
"hidden": {
"total": 8,
"http://xbrl.sec.gov/ffd/2025q4": 6,
"http://xbrl.sec.gov/dei/2025": 2
},
"contextCount": 2,
"entityCount": 1,
"segmentCount": 1,
"elementCount": 107,
"unitCount": 3,
"baseTaxonomies": {
"http://xbrl.sec.gov/ffd/2025q4": 20,
"http://xbrl.sec.gov/dei/2025": 3
},
"report": {
"R1": {
"role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
"longName": "995210 - Document - Submission",
"shortName": "Submission",
"isDefault": "true",
"groupType": "Fee_Exhibit",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": null,
"uniqueAnchor": null
},
"R2": {
"role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
"longName": "995211 - Document - Offerings",
"shortName": "Offerings",
"isDefault": "false",
"groupType": "Fee_Exhibit",
"subGroupType": "",
"menuCat": "Cover",
"order": "2",
"firstAnchor": {
"contextRef": "offrl_1",
"name": "ffd:FeesOthrRuleFlg",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm264258d1_ex-filingfees.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "offrl_1",
"name": "ffd:FeesOthrRuleFlg",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm264258d1_ex-filingfees.htm",
"first": true,
"unique": true
}
},
"R3": {
"role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
"longName": "995215 - Document - Fees Summary",
"shortName": "Fees Summary",
"isDefault": "false",
"groupType": "Fee_Exhibit",
"subGroupType": "",
"menuCat": "Cover",
"order": "3",
"firstAnchor": {
"contextRef": "rc",
"name": "ffd:TtlOfferingAmt",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm264258d1_ex-filingfees.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "rc",
"name": "ffd:TtlOfferingAmt",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm264258d1_ex-filingfees.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"ffd_AggtRedRpPricFsclYr": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "AggtRedRpPricFsclYr",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
"terseLabel": "Aggregate Redeemed or Repurchased, FY"
}
}
},
"auth_ref": []
},
"ffd_AggtRedRpPricPrrFsclYr": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "AggtRedRpPricPrrFsclYr",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
"terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
}
}
},
"auth_ref": []
},
"ffd_AggtSalesPricFsclYr": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "AggtSalesPricFsclYr",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Sales Price, Fiscal Year",
"terseLabel": "Aggregate Sales Price"
}
}
},
"auth_ref": []
},
"ffd_AmtRedCdts": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "AmtRedCdts",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Amount of Redemption Credits",
"terseLabel": "Redemption Credits"
}
}
},
"auth_ref": []
},
"ffd_AmtSctiesRcvd": {
"xbrltype": "nonNegativeDecimal2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "AmtSctiesRcvd",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Amount of Securities Received",
"terseLabel": "Amount of Securities Received"
}
}
},
"auth_ref": []
},
"ffd_AmtSctiesRegd": {
"xbrltype": "nonNegativeDecimal2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "AmtSctiesRegd",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Amount of Securities Registered",
"terseLabel": "Amount Registered"
}
}
},
"auth_ref": []
},
"ffd_CeasedOprsDt": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CeasedOprsDt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Ceased Operations Date",
"terseLabel": "Ceased Operations Date"
}
}
},
"auth_ref": []
},
"ffd_CfwdFormTp": {
"xbrltype": "formTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CfwdFormTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Carry Forward Form Type",
"terseLabel": "Carry Forward Form Type"
}
}
},
"auth_ref": []
},
"ffd_CfwdPrevslyPdFee": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CfwdPrevslyPdFee",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Carry Forward Previously Paid Fee",
"terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward"
}
}
},
"auth_ref": []
},
"ffd_CfwdPrrFctvDt": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CfwdPrrFctvDt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Carry Forward Prior Effective Date",
"terseLabel": "Carry Forward Initial Effective Date"
}
}
},
"auth_ref": []
},
"ffd_CfwdPrrFileNb": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CfwdPrrFileNb",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Carry Forward File Number",
"terseLabel": "Carry Forward File Number"
}
}
},
"auth_ref": []
},
"ffd_CmbndPrspctsItemAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CmbndPrspctsItemAxis",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Combined Prospectus Item [Axis]",
"terseLabel": "Combined Prospectus"
}
}
},
"auth_ref": []
},
"ffd_CmbndPrspctsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CmbndPrspctsLineItems",
"lang": {
"en-us": {
"role": {
"label": "Combined Prospectus [Line Items]",
"terseLabel": "Combined Prospectus:"
}
}
},
"auth_ref": []
},
"ffd_CmbndPrspctsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CmbndPrspctsTable",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Combined Prospectus [Table]",
"terseLabel": "Combined Prospectus Table"
}
}
},
"auth_ref": []
},
"ffd_CombinedProspectusTableNa": {
"xbrltype": "naItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CombinedProspectusTableNa",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Combined Prospectus Table [N/A]",
"terseLabel": "Combined Prospectus Table N/A"
}
}
},
"auth_ref": []
},
"ffd_CshPdByRegistrantInTx": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CshPdByRegistrantInTx",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Cash Paid by Registrant in Transaction",
"terseLabel": "Cash Consideration Paid"
}
}
},
"auth_ref": []
},
"ffd_CshRcvdByRegistrantInTx": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "CshRcvdByRegistrantInTx",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Cash Received by Registrant in Transaction",
"terseLabel": "Cash Consideration Received"
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"terseLabel": "Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityRegistrantName",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"terseLabel": "Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r0"
]
},
"ffd_FeeAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeeAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fee Amount",
"terseLabel": "Amount of Registration Fee"
}
}
},
"auth_ref": []
},
"ffd_FeeExhibitTp": {
"xbrltype": "feeExhibitTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeeExhibitTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fee Exhibit Type",
"terseLabel": "Fee Exhibit Type"
}
}
},
"auth_ref": []
},
"ffd_FeeIntrstAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeeIntrstAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fee Interest Amount",
"terseLabel": "Interest Amount"
}
}
},
"auth_ref": []
},
"ffd_FeeNote": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeeNote",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fee Note",
"terseLabel": "Fee Note"
}
}
},
"auth_ref": []
},
"ffd_FeeNoteMaxAggtOfferingPric": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeeNoteMaxAggtOfferingPric",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fee Note Maximum Aggregate Offering Price",
"terseLabel": "Fee Note MAOP"
}
}
},
"auth_ref": []
},
"ffd_FeeRate": {
"xbrltype": "percentItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeeRate",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fee Rate",
"terseLabel": "Fee Rate"
}
}
},
"auth_ref": []
},
"ffd_FeesOthrRuleFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeesOthrRuleFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fees, Other Rule [Flag]",
"terseLabel": "Other Rule"
}
}
},
"auth_ref": []
},
"ffd_FeesSummaryLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FeesSummaryLineItems",
"lang": {
"en-us": {
"role": {
"label": "Fees Summary [Line Items]",
"terseLabel": "Fees Summary:"
}
}
},
"auth_ref": []
},
"ffd_FnlPrspctsFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FnlPrspctsFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Final Prospectus [Flag]",
"terseLabel": "Final Prospectus"
}
}
},
"auth_ref": []
},
"ffd_FormTp": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "FormTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Form Type",
"terseLabel": "Form Type"
}
}
},
"auth_ref": []
},
"ffd_GnlInstrIIhiFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "GnlInstrIIhiFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "General Instruction II.H,I [Flag]",
"terseLabel": "General Instruction II.H,I"
}
}
},
"auth_ref": []
},
"ffd_IssrBizAdrCity": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "IssrBizAdrCity",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Issuer Business Address, City",
"terseLabel": "City"
}
}
},
"auth_ref": []
},
"ffd_IssrBizAdrStatOrCtryCd": {
"xbrltype": "stateOrCountryCodeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "IssrBizAdrStatOrCtryCd",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Issuer Business Address, State or Country Code",
"terseLabel": "State or Country Code"
}
}
},
"auth_ref": []
},
"ffd_IssrBizAdrStrt1": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "IssrBizAdrStrt1",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Issuer Business Address, Street 1",
"terseLabel": "Street 1"
}
}
},
"auth_ref": []
},
"ffd_IssrBizAdrStrt2": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "IssrBizAdrStrt2",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Issuer Business Address, Street 2",
"terseLabel": "Street 2"
}
}
},
"auth_ref": []
},
"ffd_IssrBizAdrZipCd": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "IssrBizAdrZipCd",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Issuer Business Address, Zip Code",
"terseLabel": "Zip Code"
}
}
},
"auth_ref": []
},
"ffd_IssrNm": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "IssrNm",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Issuer Name",
"terseLabel": "Issuer Name"
}
}
},
"auth_ref": []
},
"ffd_MaxAggtOfferingPric": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "MaxAggtOfferingPric",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum Aggregate Offering Price",
"terseLabel": "Maximum Aggregate Offering Price"
}
}
},
"auth_ref": []
},
"ffd_MaxOfferingPricPerScty": {
"xbrltype": "nonNegativeDecimal4lItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "MaxOfferingPricPerScty",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum Offering Price per Security",
"terseLabel": "Proposed Maximum Offering Price per Unit"
}
}
},
"auth_ref": []
},
"ffd_NetFeeAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "NetFeeAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Net Fee Amount",
"terseLabel": "Net Fee"
}
}
},
"auth_ref": []
},
"ffd_NetSalesAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "NetSalesAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Net Sales Amount",
"terseLabel": "Net Sales"
}
}
},
"auth_ref": []
},
"ffd_NrrtvDsclsr": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "NrrtvDsclsr",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Narrative Disclosure",
"terseLabel": "Narrative Disclosure"
}
}
},
"auth_ref": []
},
"ffd_NrrtvMaxAggtAmt": {
"xbrltype": "nonNegativeDecimal2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "NrrtvMaxAggtAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
"terseLabel": "Narrative - Max Aggregate Offering Amount"
}
}
},
"auth_ref": []
},
"ffd_NrrtvMaxAggtOfferingPric": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "NrrtvMaxAggtOfferingPric",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Narrative Disclosure, Maximum Aggregate Offering Price",
"terseLabel": "Narrative - Max Aggregate Offering Price"
}
}
},
"auth_ref": []
},
"ffd_OfferingAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OfferingAxis",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offering [Axis]",
"terseLabel": "Offering"
}
}
},
"auth_ref": []
},
"ffd_OfferingLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OfferingLineItems",
"lang": {
"en-us": {
"role": {
"label": "Offering [Line Items]",
"terseLabel": "Offering:"
}
}
},
"auth_ref": []
},
"ffd_OfferingNote": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OfferingNote",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offering Note",
"terseLabel": "Offering Note"
}
}
},
"auth_ref": []
},
"ffd_OfferingSctyTitl": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OfferingSctyTitl",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offering Security Title",
"terseLabel": "Security Class Title"
}
}
},
"auth_ref": []
},
"ffd_OfferingSctyTp": {
"xbrltype": "securityTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OfferingSctyTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offering Security Type",
"terseLabel": "Security Type"
}
}
},
"auth_ref": []
},
"ffd_OfferingTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OfferingTable",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offering [Table]",
"terseLabel": "Offering:"
}
}
},
"auth_ref": []
},
"ffd_OfferingTableNa": {
"xbrltype": "naItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OfferingTableNa",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offering Table [N/A]",
"terseLabel": "Offering Table N/A"
}
}
},
"auth_ref": []
},
"ffd_OffsetAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetAxis",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset [Axis]",
"terseLabel": "Offset"
}
}
},
"auth_ref": []
},
"ffd_OffsetClmInitlFilgDt": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetClmInitlFilgDt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Claim Initial Filing Date",
"terseLabel": "Initial Filing Date"
}
}
},
"auth_ref": []
},
"ffd_OffsetClmdAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetClmdAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Claimed Amount",
"terseLabel": "Fee Offset Claimed"
}
}
},
"auth_ref": []
},
"ffd_OffsetClmdInd": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetClmdInd",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Claimed Indicator",
"terseLabel": "Offset Claimed"
}
}
},
"auth_ref": []
},
"ffd_OffsetExpltnForClmdAmt": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetExpltnForClmdAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Explanation for Claimed Amount",
"terseLabel": "Explanation for Claimed Amount"
}
}
},
"auth_ref": []
},
"ffd_OffsetLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetLineItems",
"lang": {
"en-us": {
"role": {
"terseLabel": "Offset:",
"label": "Offset [Line Items]"
}
}
},
"auth_ref": []
},
"ffd_OffsetNote": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetNote",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Note",
"terseLabel": "Offset Note"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrFeeAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrFeeAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior Fee Amount",
"terseLabel": "Fee Paid with Fee Offset Source"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrFileNb": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrFileNb",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior File Number",
"terseLabel": "File Number"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrFilerNm": {
"xbrltype": "filerNameItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrFilerNm",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior Filer Name",
"terseLabel": "Registrant or Filer Name"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrFormTp": {
"xbrltype": "formTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrFormTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior Form Type",
"terseLabel": "Form or Filing Type"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrNbOfUnsoldScties": {
"xbrltype": "nonNegativeDecimal8ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrNbOfUnsoldScties",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior Unsold Number of Securities",
"terseLabel": "Unsold Securities Associated with Fee Offset Claimed"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrSctyTitl": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrSctyTitl",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior Security Title",
"terseLabel": "Security Title Associated with Fee Offset Claimed"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrSctyTp": {
"xbrltype": "securityTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrSctyTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior Security Type",
"terseLabel": "Security Type Associated with Fee Offset Claimed"
}
}
},
"auth_ref": []
},
"ffd_OffsetPrrUnsoldOfferingAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetPrrUnsoldOfferingAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Prior Unsold Offering Amount",
"terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed"
}
}
},
"auth_ref": []
},
"ffd_OffsetSrcFilgDt": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetSrcFilgDt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Source Filing Date",
"terseLabel": "Filing Date"
}
}
},
"auth_ref": []
},
"ffd_OffsetTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetTable",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Offset Payment:",
"label": "Offset [Table]"
}
}
},
"auth_ref": []
},
"ffd_OffsetTableNa": {
"xbrltype": "naItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "OffsetTableNa",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Offset Table [N/A]",
"terseLabel": "Offset Table N/A"
}
}
},
"auth_ref": []
},
"ffd_PrevslyPdFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "PrevslyPdFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Fee Previously Paid [Flag]",
"terseLabel": "Fee Previously Paid"
}
}
},
"auth_ref": []
},
"ffd_RegnFileNb": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "RegnFileNb",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Registration File Number",
"terseLabel": "Registration File Number"
}
}
},
"auth_ref": []
},
"ffd_RptgFsclYrEndDt": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "RptgFsclYrEndDt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Reporting Fiscal Year End Date",
"terseLabel": "Reporting FY End Date"
}
}
},
"auth_ref": []
},
"ffd_Rule011Flg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule011Flg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 0-11 [Flag]",
"terseLabel": "Rule 0-11"
}
}
},
"auth_ref": []
},
"ffd_Rule011a2OffsetFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule011a2OffsetFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Rule 0-11(a)(2) Offset",
"label": "Rule 0-11(a)(2) Offset [Flag]"
}
}
},
"auth_ref": []
},
"ffd_Rule415a6Flg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule415a6Flg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 415(a)(6) [Flag]",
"terseLabel": "Rule 415(a)(6)"
}
}
},
"auth_ref": []
},
"ffd_Rule429AggtOfferingAmt": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429AggtOfferingAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Aggregate Offering Amount",
"terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered"
}
}
},
"auth_ref": []
},
"ffd_Rule429CmbndPrspctsFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429CmbndPrspctsFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Combined Prospectus [Flag]",
"terseLabel": "Rule 429"
}
}
},
"auth_ref": []
},
"ffd_Rule429EarlierFileNb": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429EarlierFileNb",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Earlier File Number",
"terseLabel": "File Number"
}
}
},
"auth_ref": []
},
"ffd_Rule429EarlierFormTp": {
"xbrltype": "formTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429EarlierFormTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Earlier Form Type",
"terseLabel": "Form Type"
}
}
},
"auth_ref": []
},
"ffd_Rule429InitlFctvDt": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429InitlFctvDt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Initial Effective Date",
"terseLabel": "Initial Effective Date"
}
}
},
"auth_ref": []
},
"ffd_Rule429NbOfUnsoldScties": {
"xbrltype": "nonNegativeDecimal2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429NbOfUnsoldScties",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Number Of Unsold Securities",
"terseLabel": "Amount of Securities Previously Registered"
}
}
},
"auth_ref": []
},
"ffd_Rule429PrspctsNote": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429PrspctsNote",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Prospectus Note",
"terseLabel": "Combined Prospectus Note"
}
}
},
"auth_ref": []
},
"ffd_Rule429SctyTitl": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429SctyTitl",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Security Title",
"terseLabel": "Security Class Title"
}
}
},
"auth_ref": []
},
"ffd_Rule429SctyTp": {
"xbrltype": "securityTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule429SctyTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 429 Security Type",
"terseLabel": "Security Type"
}
}
},
"auth_ref": []
},
"ffd_Rule457aFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457aFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(a) [Flag]",
"terseLabel": "Rule 457(a)"
}
}
},
"auth_ref": []
},
"ffd_Rule457bOffsetFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457bOffsetFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(b) Offset [Flag]",
"terseLabel": "Rule 457(b) Offset"
}
}
},
"auth_ref": []
},
"ffd_Rule457fFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457fFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(f) [Flag]",
"terseLabel": "Rule 457(f)"
}
}
},
"auth_ref": []
},
"ffd_Rule457oFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457oFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(o) [Flag]",
"terseLabel": "Rule 457(o)"
}
}
},
"auth_ref": []
},
"ffd_Rule457pOffsetFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457pOffsetFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(p) Offset [Flag]",
"terseLabel": "Rule 457(p) Offset"
}
}
},
"auth_ref": []
},
"ffd_Rule457rFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457rFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(r) [Flag]",
"terseLabel": "Rule 457(r)"
}
}
},
"auth_ref": []
},
"ffd_Rule457sFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457sFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(s) Flag",
"terseLabel": "Rule 457(s)"
}
}
},
"auth_ref": []
},
"ffd_Rule457uFlg": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Rule457uFlg",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 457(u) [Flag]",
"terseLabel": "Rule 457(u)"
}
}
},
"auth_ref": []
},
"ffd_Scties424iAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Scties424iAxis",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Securities, 424I [Axis]",
"terseLabel": "Securities, 424I"
}
}
},
"auth_ref": []
},
"ffd_Scties424iLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Scties424iLineItems",
"lang": {
"en-us": {
"role": {
"label": "Securities, 424I [Line Items]",
"terseLabel": "Securities, 424I:"
}
}
},
"auth_ref": []
},
"ffd_Scties424iTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Scties424iTable",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/securities424iTable"
],
"lang": {
"en-us": {
"role": {
"label": "Securities, 424I [Table]",
"terseLabel": "Securities, 424I Table"
}
}
},
"auth_ref": []
},
"ffd_Securities424iTableNa": {
"xbrltype": "naItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "Securities424iNa",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Securities 424I [N/A]",
"terseLabel": "Securities 424I N/A"
}
}
},
"auth_ref": []
},
"ffd_SubmissionLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "SubmissionLineItems",
"lang": {
"en-us": {
"role": {
"label": "Submission [Line Items]",
"terseLabel": "Items"
}
}
},
"auth_ref": []
},
"ffd_SubmissnTp": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "SubmissnTp",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/submissionTable"
],
"lang": {
"en-us": {
"role": {
"label": "Submission Type",
"terseLabel": "Submission Type"
}
}
},
"auth_ref": []
},
"ffd_TermntnCmpltnWdrwl": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TermntnCmpltnWdrwl",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
],
"lang": {
"en-us": {
"role": {
"label": "Termination / Completion / Withdrawal Statement",
"terseLabel": "Termination / Withdrawal Statement"
}
}
},
"auth_ref": []
},
"ffd_TtlFeeAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TtlFeeAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Total Fee Amount",
"terseLabel": "Total Fee Amount"
}
}
},
"auth_ref": []
},
"ffd_TtlFeeAndIntrstAmt": {
"xbrltype": "nonNegativeDecimal2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TtlFeeAndIntrstAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Total Fee and Interest Amount",
"terseLabel": "Total Fee and Interest Amount"
}
}
},
"auth_ref": []
},
"ffd_TtlOfferingAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TtlOfferingAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Total Offering Amount",
"terseLabel": "Total Offering"
}
}
},
"auth_ref": []
},
"ffd_TtlOffsetAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TtlOffsetAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Total Offset Amount",
"terseLabel": "Total Offset Amount"
}
}
},
"auth_ref": []
},
"ffd_TtlPrevslyPdAmt": {
"xbrltype": "nonNegative1TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TtlPrevslyPdAmt",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Total Previously Paid Amount",
"terseLabel": "Previously Paid Amount"
}
}
},
"auth_ref": []
},
"ffd_TtlTxValtn": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TtlTxValtn",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
],
"lang": {
"en-us": {
"role": {
"label": "Total Transaction Valuation",
"terseLabel": "Total Transaction Valuation"
}
}
},
"auth_ref": []
},
"ffd_TxValtn": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "TxValtn",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Transaction Valuation",
"terseLabel": "Transaction Valuation"
}
}
},
"auth_ref": []
},
"ffd_ValSctiesRcvd": {
"xbrltype": "nonNegative100TMonetary2ItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "ValSctiesRcvd",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Value of Securities Received",
"terseLabel": "Value of Securities Received"
}
}
},
"auth_ref": []
},
"ffd_ValSctiesRcvdPerShr": {
"xbrltype": "nonNegativeDecimal4lItemType",
"nsuri": "http://xbrl.sec.gov/ffd/2025q4",
"localname": "ValSctiesRcvdPerShr",
"presentation": [
"http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
],
"lang": {
"en-us": {
"role": {
"label": "Value of Securities Received, Per Share",
"terseLabel": "Value of Securities Received, Per Share"
}
}
},
"auth_ref": []
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
}
}
}